Secondary Logo

Journal Logo

Reading and citing from the Journal of Hypertension

Zanchetti, Alberto

doi: 10.1097/HJH.0b013e328306091b
Editor's corner
Free

Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Università di Milano, and Istituto Auxologico Italiano, Milan, Italy

Correspondence to Alberto Zanchetti, Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Università di Milano, Via F. Sforza 35, 20122 Milan, Italy

With the valuable help of Phil Daly, senior publisher at Lippincott Williams & Wilkins, the publishers of Journal of Hypertension (for web analysis), and of Mrs Mara Bernardinello, librarian of the Istituto Auxologico Italiano (for scientific citations), summary information is again presented on full-text article downloading from the Journal of Hypertension website during 2007, and on the journal articles published in 2005 and 2006 that have been most frequently cited by peer-reviewed publications in the period up to 31 December 2007.

Back to Top | Article Outline

Full article and abstract downloading

During 2007, there were 191 486 full-text article requests. Full-text requests for the 30 most frequently downloaded articles span widely from 3464 (the 2007 ESH-ESC guidelines) to 259. Among the top 30 articles, six are Guidelines, 11 Reviews, three Meta-analyses, four are Editorial Commentaries or Editorials or Debates, and six are Original Papers. The majority of the downloaded papers were published during 2007, but papers from previous years have also been frequently requested.

1 The Task Force for the Management of Arterial Hypertenison of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J. Hypertens 2007; 25: 1105–1187 (Guidelines).

2 ESH-ESC Task Force on the Management of Hypertension. 2007 ESH-ESC practice guidelines for the management of Hypertension. J. Hypertens 2007; 25: 1751–1762 (Guidelines).

3 Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertens 2007; 25: 951–9587 (Meta-analysis).

4 Unger T. The Bjorn Folkow Award Lecture. The angiotensin type 2 receptor: variations on an enigmatic theme. J. Hypertens 1999; 17: 1775–1780 (Review).

5 Guideline Committee. 2003 European Society of Hypertension: European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens 2003; 21: 1011–1053 (Guidelines).

6 World Health Organization: Internatioanl Society of Hypertension Writing Group. 2003 World Health Organization (WHO): International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens 2003; 21: 1983–1992 (Guidelines).

7 Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens 2007; 25: 217–226 (Original Paper).

8 Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens 2006; 24: 243–256 (Review).

9 Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J. Hypertens 2007; 25: 909–920 (Review).

10 Calò LA, Pessina AC. Rho/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J. Hypertens 2007; 25: 259–264 (Review).

11 Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J. Hypertens 2007; 25: 25–35 (Review).

12 Alderman MH. Dietary sodium and cardiovascular disease: the J-shaped relation. J. Hypertens 2007; 25: 903–907 (Review).

13 Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens 2003; 21: 875–886 (Original Paper).

14 Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J. Hypertens 2007; 25: 1327–1336 (Review).

15 Hollenberg NK, Parving H-H, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J. Hypertens 2007; 25: 1921–1926 (Original Paper).

16 Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J. Hypertens 2007; 25: 841–848 (Original Paper).

17 Parati G, Ibsen H. Twenty-four-hour ambulatory blood pressure profiles of high-risk patients in general practice: data from an ambulatory blood pressure monitoring registry. J. Hypertens 2007; 25: 929–933 (Editorial Comment).

18 Gorostidi M, Sobrino J, Segura J, Sierra C. de la Sierra A, Hernandez del Rey R, et al. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20 000-patient database in Spain. J. Hypertens 2007; 25: 977–984 (Original Paper).

19 Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J. Hypertens 2007; 25: 731–741 (Review).

20 Ménard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J. Hypertens 2007; 25: 1775–1782 (Editorial).

21 Lederballe Pedersen O, Mancia G, Pickering T, Hoegholm A, Julius S, Kjeldsen SE, et al. Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. J. Hypertens 2007; 25: 707–712 (Original Paper).

22 Zannad F. Aldosterone antagonist therapy in resistant hypertension. J. Hypertens 2007; 25: 747–750 (Editorial Comment).

23 Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J. Hypertens 2006; 24: 2131–2141 (Review).

24 Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J. Hypertens 2004; 22: 11–19 (Review).

25 O'Brien E, Asmar R, Beilin L, Imai Y, Mallion J-M, Mancia G, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J. Hypertens 2003; 21: 821–848 (Guidelines).

26 Practice Guidelines Writing Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J. Hypertens 2003; 21: 1779–1786 (Guidelines).

27 McInnes GT. What is the true place of blood pressure in cardiovascular risk management? J. Hypertens 2007; 25: 925–928 (Debate).

28 Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J. Hypertens 2007; 25: 2193–2198 (Meta-analysis).

29 Protogerou AD, Papaioannou TG, Blacher J, Papamichael CM, Lekakis JP, Safar ME. Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target? J. Hypertens 2007; 25: 265–272 (Review)

30 Boutitie F, Oprisiu R, Achard JM, Mazouz H, Wanag J, Messerli FH, et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J. Hypertens 2007; 25: 1543–1553 (Meta-analysis)

Back to Top | Article Outline

Citations

Articles published in volume 23 of the Journal of Hypertension (2005) received 2506 citations by 31 December 2007. Eighty-seven have received at least 10 citations: 20 were Reviews or Meta-analyses, one was an Editorial Comment and 66 were Original Papers (19 on basic research). The 27 articles (of which 18 were Original Papers) that received 20 or more citations are listed below.

1 Brunner H, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens 2005; 23: 233–246 (Review).

2 Jandeleit-Dahm KAM, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens 2005; 23: 463–473 (Review).

3 O'Brien E, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J. Hypertens 2005; 23: 697–701 (Guidelines).

4 Deanfield J, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J. Hypertens 2005; 23: 7–17 (Review).

5 Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery? J. Hypertens 2005; 23: 551–556 (Original Paper).

6 Lubsen J, Wagener G, Kirwan B-A, De Brouwer S, Poole-Wilson PA. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J. Hypertens 2005; 23: 641–648 (Original paper).

7 Fratta-Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J. Hypertens 2005; 23: 589–596 (Original Paper)

8 Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J. Hypertens 2005; 23: 97–104 (Original Paper).

9 Olsen MH, Ibsen H, Kjeldsen SE, Julius S, Fossum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J. Hypertens 2005; 23: 891–898 (Original Paper).

10 Cornelissen VA, Fagard RH. Effect of resistance training on resting blood pressure: a meta-analysis of randomized controlled trials. J. Hypertens 2005; 23: 251–259 (Review).

11 Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens 2005; 23: 2157–2172 (Original Paper).

12 Mason MJ, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J. Hypertens 2005; 23: 1777–1781 (Original Paper).

13 Noordzij M, Uiterwall CSPM, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J. Hypertens 2005; 23: 921–928 (Review).

14 Potter JF. CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design. J. Hypertens 2005; 23: 649–655 (Original Paper).

15 Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens 2005; 23: 417–426 (Original Paper).

16 Obara T, Imai Y, Ohkubo T, Funahashi J, Kikuya M, Asayama K, et al. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. J. Hypertens 2005; 23: 1653–1660 (Original Paper).

17 Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens 2005; 23: 1725–1729 (Original Paper).

18 Cuspidi C, Meani S, Fusi V, Valerio C, Catini E, Sala C, et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome. The Evaluation of Target Organ Damage in Hypertension study. J. Hypertens 2005; 23: 875–882 (Original Paper).

19 Jourdan C, Troger J, Schaefer F, Wuhl E, Litwin M, Fahr K, et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J. Hypertens 2005; 23: 1707–1715 (Original Paper).

20 Mita S-I, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J. Hypertens 2005; 23: 87–96 (Original Paper).

21 Marteau J-B, Zaiou M, Siest G, Visvikis-Siest G. Genetic determinants of blood pressure regulation. J. Hypertens 2005; 23: 2127–2143 (Review).

22 Zabekakis PE, Nawrot T, Thijs L, Balkestein EJ, Van Der Heijden-Spek J, Van Bortel LM, et al. Obesity is associated with increased arterial stiffness from adolescence until old age. J. Hypertens 2005; 23: 1839–1846 (Original Paper).

23 Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J. Hypertens 2005; 23: 1831–1837 (Original Paper).

24 Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J. Hypertens 2005; 23: 1311–1325 (Review).

25 Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J. Hypertens 2005; 23: 1113–1120 (Review).

26 Haffner D, Nissel R, Querfeld U, Hocher B. Muller D, Simon K, et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH) 2D3. J. Hypertens 2005; 23: 1067–1075 (Original Paper).

27 Bombelli M, Primitz L, Mancia G, Sega R, Facchetti R, Corrao G, et al. Prevalence and clinical sisgnificance of a greater ambulatory versus office blood pressure (‘reversed white-coat’ condition) in a general population. J. Hypertens 2005; 23: 513–520 (Original Paper).

Despite the short time elapsed from publication, articles published in the Journal of Hypertension during 2006 (volume 24) received a remarkable number of citations by the end of 2007, namely 1603. Forty-seven papers (of which 15 were Reviews) received at least 10 citations, and 10 papers at least 20 citations. The top 10 articles are listed below.

1 Song JH, Cha SH, Hong SB, KimDH. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J. Hypertens 2006; 24 (Suppl. 1): S101–S106 (Review).

2 Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J. Hypertens 2006; 24: 3–10 (Review).

3 Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J. Hypertens 2006; 24: 215–223 (Review).

4 Burnier M, Zanchi A. Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J. Hypertens 2006; 24: 11–25 (Review).

5 Kjeldsen SE, Jamerson K, Larochelle P, MacDonald TM, Schmider RE, Schork MA, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens 2006; 24: 1405–1412 (Original Paper).

6 Celik T, Isik E, Fici F, Iyisoy A, Kursaklioglu H, Kardesoglu E, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens 2006; 24: 591–596 (Original Paper).

7 Lawes CMM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J. Hypertens 2006; 24: S101–S106 (Original Paper).

8 Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as a first-line therapy for hypertension? Systematic review and meta-analysis. J. Hypertens 2006; 24: 2131–2141 (Review).

9 Palatini P, Ruilope LM, Zanchetti A, Benetos A, Grassi G, Julius S, et al. Identification and management of the hypertensive patient with elevated heart rate: Statement of a European Society of Hypertension Consensus Meeting. J. Hypertens 2006; 24: 603–610 (Review).

10 Lawes CMM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part I: estimates of blood pressure levels. J. Hypertens 2006; 24: 413–422 (Original Paper).

Back to Top | Article Outline

Comments

Judging from downloads from the Journal of Hypertension website, the immediate interest of readers apparently concentrates on guidelines, reviews and meta-analyses, with a number of editorial commentaries also being widely read. Longer term effects on science, as gauged from citations in peer-reviewed journals, obviously depend on original articles, although guidelines, reviews and meta-analyses are also often cited particularly as a useful means of summarizing the state of knowledge.

© 2008 Lippincott Williams & Wilkins, Inc.